OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
$4,76
arrow_upward
+0,85%(+0,040) 1G
13 Eki, 16:00:00 GMT-4 · USD
search
Tüm semboller
| Sembol | Fiyat | Değişiklik | Değişiklik % |
|---|
insights_autoOPHLY ile ilgili en önemli analizler oluşturuluyor...
Açık
$4,78
Yüksek
$4,78
Düşük
$4,76
Piy. değ.
1,13 Tn
Ort. hacim
60,13 B
İşlem Hacmi
82,82 B
52 haftalık en yüksek
$5,75
52 haftalık en düşük
$3,81
Beta
0,21
Tedavüldeki hisse senedi sayısı
1,50 Mr
Çalışan sayısı
4 B
Açık
$4,78
Yüksek
$4,78
Düşük
$4,76
Piy. değ.
1,13 Tn
Ort. hacim
60,13 B
İşlem Hacmi
82,82 B
52 haftalık en yüksek
$5,75
52 haftalık en düşük
$3,81
Beta
0,21
Tedavüldeki hisse senedi sayısı
1,50 Mr
Çalışan sayısı
4 B
Haberler
Web kaynaklarından ve haber iş ortaklarından
Northwest Arkansas Democrat-Gazette
·
9 dakika önce
Summertime reports make waves on Wall Street
MarketBeat
·
44 dakika önce
People Incorporated Common Stock (NASDAQ:PPLI) Stock Has Average Price Target of $56.08
Stocktwits
·
1 saat önce
UNH Stock Outpaces S&P 500 In 2026, Eyes Best Year Since Pandemic — CFO Says Wall Street May Be Missing 2027 Upside
Yahoo Finance
·
1 saat önce
Stock Market: Will S&P 500 Open Up or Down Today?
Profil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs hakkında
CEOGyo Sagara | Gyo Sagara
Çalışan Sayısı4,21 B
Kuruluş Tarihi1717
Genel MerkezOsaka, Osaka ili, Japonya
Sektör-
Web Sitesiono-pharma.com